A patent granted to Compass Pathways is drawing attention to how pharmaceutical companies might end up owning forms of long-established psychedelic substances. Part 2 of a 3-part series.
Tactics used by Compass Pathways common to pharma companies pose ethical questions for the emerging psychedelics industry. Part one of a three-part series.